Specialty Clinical Updates

Cardiology Clinical Coverage

Specialty-focused drug approvals, safety updates, trial context, and clinical reference coverage for healthcare professionals.

Clinical Coverage

Search clinical updates and clinical coverage.

12 loaded

Cardiology

FDA Approves Baxdrostat for Resistant Hypertension: 10 mmHg SBP Reduction in BaxHTN Trial

Baxdrostat: 10 mmHg SBP reduction in resistant hypertension from the BaxHTN trial. FDA approval confirmed.

Jun 13|4 min read|Dr. Kavya Sharma

Cardiology

FDA Approves Empagliflozin for HFpEF: 21% Heart Failure Hospitalization Reduction in EMPEROR-Preserved Trial

Empagliflozin reduces heart failure hospitalization by 21% in EMPEROR-Preserved trial, approved for HFpEF treatment.

Jun 10|4 min read|Dr. Arjun Sharma

Cardiology

FDA Approves Semaglutide for HFpEF: 13.3% KCCQ Score Improvement in STEP-HFpEF Trial

Semaglutide (Wegovy) shows 13.3% KCCQ score improvement in HFpEF patients in STEP-HFpEF trial.

Jun 9|4 min read|Dr. Kavya Sharma

Cardiology

FDA Approves Baxdrostat for Hypertension: First-in-Class Aldosterone Synthase Inhibitor

Baxdrostat reduces resistant hypertension: 11.1 mmHg SBP reduction in BaxHTN trial.

Jun 9|4 min read|Dr. Arjun Sharma

Cardiology

FDA Approves Olezarsen for Severe Hypertriglyceridemia: 42.5% TG Reduction in Familial Chylomicronemia Syndrome

Olezarsen approved for severe hypertriglyceridemia: 42.5% TG reduction in familial chylomicronemia syndrome.

Jun 8|4 min read|Dr. Kavya Sharma

Cardiology

FDA Approves Etripamil (Cardamyst) for PSVT: Rapid Conversion to Sinus Rhythm in Outpatient Settings

FDA approves etripamil (Cardamyst) nasal spray for rapid conversion of paroxysmal supraventricular tachycardia episodes.

Jun 6|4 min read|Dr. Kavya Sharma

Cardiology

Abelacimab Reduces Stroke Risk: AZALEA-TIMI 71 Trial Shows Improved Safety Profile in Atrial Fibrillation

Abelacimab reduces stroke risk by 30% in AZALEA-TIMI 71 trial, showing improved safety in atrial fibrillation patients.

Jun 6|5 min read|Dr. Kavya Sharma

Cardiology

Baxdrostat Reduces Resistant Hypertension: New Treatment Algorithm for 2026

Baxdrostat reduces resistant hypertension: new 2026 treatment algorithm emphasizes structured management for better outcomes.

May 29|3 min read|Dr. Kavya Sharma

Cardiology

FDA Approves Semaglutide for PAD: STRIDE Trial Shows Improved Walking Distance

Semaglutide approved for PAD: STRIDE trial shows improved walking distance, offering new treatment options for patients.

May 26|3 min read|Dr. Kavya Sharma

Cardiology

Aficamten Reduces Symptoms by 30% in Obstructive HCM: 2025 Clinical Algorithm Update

Aficamten reduces symptoms by 30% in obstructive HCM, impacting treatment strategies for 2025.

May 21|3 min read|Dr. Arjun Sharma

Cardiology

ACC Updates HFpEF Guidelines: SGLT2 Inhibitors and GLP-1 Agonists Recommended

ACC updates HFpEF guidelines: SGLT2 inhibitors and GLP-1 agonists recommended for improved patient outcomes.

May 20|3 min read|Dr. Arjun Sharma

Cardiology

Enlicitide Reduces LDL Cholesterol Significantly in Phase 3 Trial

Enlicitide reduces LDL cholesterol by 47% in HeFH patients, offering a new oral PCSK9 inhibitor option.

May 7|3 min read|Dr. Arjun Sharma